Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208

被引：0
|
作者：
Hochster, H. [1 ]
Catalano, Paul J. [2 ]
O'Dwyer, Peter J. [3 ]
Mitchell, Edith P. [4 ]
Cohen, Deirdre Jill [5 ,6 ]
Faller, Bryan Andrew [7 ]
Kortmansky, Jeremy S. [8 ]
Kircher, Sheetal Mehta [9 ]
Lacy, Jill [10 ]
Lenz, Heinz-Josef [11 ]
Verma, Udit N. [12 ]
Benson, Al Bowen, III [13 ]
机构：
[1] Rutgers Canc Inst, New Brunswick, NJ USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[4] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[5] NYU Perlmutter Canc Ctr, New York, NY USA
[6] ECOG ACRIN, New York, NY USA
[7] Midwest Hem & Onc Assoc, Clayton, MO USA
[8] Med Oncol & Hematol, Hamden, CT USA
[9] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
[10] Yale Univ, Smilow Canc Hosp, New Haven, CT USA
[11] Univ Southern Calif, Los Angeles, CA USA
[12] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[13] Northwestern Med, Chicago, IL USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O - 030
引用
收藏
页数：1
相关论文
共 38 条
  • [1] Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208.
    Hochster, Howard S.
    Catalano, Paul J.
    O'Dwyer, Peter J.
    Mitchell, Edith P.
    Cohen, Deirdre Jill
    Faller, Bryan Andrew
    Kortmansky, Jeremy S.
    Kircher, Sheetal Mehta
    Lacy, Jill
    Lenz, Heinz-Josef
    Verma, Udit N.
    Benson, Al Bowen
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second line therapy of KRAS wild type colorectal cancer (CRC).
    Hochster, Howard S.
    Catalano, Paul J.
    Mitchell, Edith P.
    Cohen, Deirdre Jill
    O'Dwyer, Peter J.
    Benson, Al Bowen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [3] E7208: A randomized phase II trial of irinotecan and cetuximab (IC) versus IC plus ramucirumab (ICR) in second-line therapy of KRAS wild-type colorectal cancer (CRC).
    Hochster, Howard S.
    Catalano, Paul J.
    Mitchell, Edith P.
    Cohen, Deirdre Jill
    O'Dwyer, Peter J.
    Benson, Al Bowen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil
    Pfeiffer, Per
    Nielsen, Dorte
    Yilmaz, Mette
    Iversen, Anja
    Vejlo, Christian
    Jensen, Benny Vittrup
    ACTA ONCOLOGICA, 2007, 46 (05) : 697 - 701
  • [5] Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil
    Pfeiffer, P.
    Nielsen, D.
    Bjerregaard, J.
    Qvortrup, C.
    Yilmaz, M.
    Jensen, B.
    ANNALS OF ONCOLOGY, 2008, 19 (06) : 1141 - 1145
  • [6] Cetuximab plus capecitabine/irinotecan (XELIRI) versus cetuximab plus capecitabine/oxaliplatin (XELOX) as first line treatment for patients with metastatic colorectal cancer (CRC): A randomized trial of the AIO CRC study group
    Von Weikersthal, Ludwig Fischer
    Moosmann, Nicolas
    Vehling-Kaiser, U.
    Stauch, Martina
    Schlimok, G.
    Schulze, M.
    Walther, J.
    Weiss, J.
    Dietzfelbinger, H.
    Heinemann, Volker
    ANNALS OF ONCOLOGY, 2006, 17 : 115 - 115
  • [7] Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial
    Vincenzi, B
    Santini, D
    Rabitti, C
    Coppola, R
    Zobel, BB
    Trodella, L
    Tonini, G
    BRITISH JOURNAL OF CANCER, 2006, 94 (06) : 792 - 797
  • [8] Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial
    B Vincenzi
    D Santini
    C Rabitti
    R Coppola
    B Beomonte Zobel
    L Trodella
    G Tonini
    British Journal of Cancer, 2006, 94 : 792 - 797
  • [9] Cetuximab plus capecitabine plus irinotecan (CCI) versus cetuximab plus capecitabine plus oxaliplatin (CCO) as first line therapy for patients with metastatic colorectal cancer (CRC): Preliminary results of a randomized phase II trial of the AIO CRC Study Group.
    Heinemann, V.
    Von Weikersthal, L. Fischer
    Moosmann, N.
    Vehling-Kaiser, U.
    Stauch, M.
    Oruzio, D.
    Schulze, M.
    Walther, J.
    Weiss, J.
    Dietzfelbinger, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 158S - 158S
  • [10] Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) failing prior oxaliplatin-based therapy: the EPIC trial
    Scheithauer, W.
    Sobrero, A.
    Lenz, H. J.
    Maurel, J.
    Lutz, M.
    Middleton, G.
    Saleh, M.
    Zubel, A.
    Williams, K.
    Burris, H. A., III
    EJC SUPPLEMENTS, 2007, 5 (04): : 235 - 236
1234